Replies to post #3373 on GTC Biotherapeutics (fka GTCB)

[alia]

some more info: re: Lucentis and German reimbursement

I just had a look at the EMEAs EPAR summary on Atryn (http://www.emea.europa.eu/humandocs/PDFs/EPAR/atryn/058706en1.pdf) and you are probably right about the Lucentis analogy and resulting off label market size for Atryn (at least for an intial time period after launch) in that they have to put special programmes in place pre-launch to monitor safety (p.2 under 'information awaited' in above doc), hence, I still think there is the potential for not insignificant (compared to HD) off-label prescribing in principle, but you may be right that that may be restricted in the short- and medium-term due to medical/safety reasons though, not reimbursement reasons per se.